From Our Partners
Saturday, June 25, 2022
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Defense + Military

DARPA Seeks Proposals for In Vivo Nanotherapeutics

by Global Biodefense Staff
June 12, 2012

The Defense Advanced Research Project Agency (DARPA) is seeking proposals for innovative technology in support of the In vivo Nanoplatforms for Therapeutics (IVN:Tx) initiative. The effort was announced in a Broad Agency Announcement (BAA) released this week.

The overall program objective is to develop radically new classes of adaptable, biocompatible nanotherapeutic platforms that can be programmed “on-the-fly” to treat military-relevant diseases.  The IVN:Tx thrust is for development of new methods to increase nanotherapeutic safety that minimizes the dose required for clinically relevant efficacy and limits immunogenicity.

IVN:Tx also seeks to develop new methods to increase nanotherapeutic effectiveness by targeting delivery to specific tissues or uptake by cells of interest, increasing bioavailability, knocking down medically relevant molecular targets, and increasing resistance to degradation. The solicitation specifically mentions that “successful nanotherapeutic platforms should enable treatment of military-relevant diseases such as infections caused by multi-drug resistant organisms and conditions due to traumatic brain injury.”

Under a separate BAA, DARPA solicited proposals to develop the nanoscale systems necessary for in vivo sensing and physiologic monitoring of warfighters as components of the In vivo Nanoplatforms for Diagnostics (IVN:Dx) thrust of the IVN program. This companion solicitation for the In vivo Nanoplatforms for Therapeutics (IVN:Tx) thrust seeks proposals describing novel nanotherapeutics with tailored sequence, specificity, and functionality to address the therapeutics objective of the program.

Together these BAAs work to will enable a versatile and rapidly adaptable system to provide medical and operational support to the warfighter in any location. DARPA encourages the development of standalone diagnostic and therapeutic technologies within each thrust in order to optimize the technologies, capabilities, and applications developed within the IVN program.  Proposals to develop small molecule therapeutics for treatment of a specific disease are not being sought under this BAA.

Full details are available under Solicitation Number: DARPA-BAA-12-34. Proposal abstracts are due July 18, 2012. The full proposal response deadline is September 18, 2012.

From Our Partners
Tags: BAADARPANanotech

Related Posts

UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control
Medical Countermeasures

UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control

June 21, 2022
Biodefense Industry News
Industry News

Tonix Pharmaceuticals Opens Advanced Development Center for Vaccine Programs

June 20, 2022
Monkeypox Cases Prompt Additional Contracts for Bavarian Nordic Vaccine
Medical Countermeasures

Monkeypox Cases Prompt Additional Contracts for Bavarian Nordic Vaccine

May 30, 2022
Novavax Missed Its Global Moonshot but Is Angling to Win Over mRNA Defectors
Industry News

Novavax Missed Its Global Moonshot but Is Angling to Win Over mRNA Defectors

May 26, 2022
Load More

Latest News

Poliovirus Detected in London Sewage: Response Measures Emphasize Wastewater Surveillance and Vaccination Gaps

Poliovirus Detected in London Sewage: Response Measures Emphasize Wastewater Surveillance and Vaccination Gaps

June 22, 2022
Monkeypox Diagnostics: CDC Authorizes Five Commercial Lab Companies

Monkeypox Diagnostics: CDC Authorizes Five Commercial Lab Companies

June 22, 2022
UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control

UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control

June 21, 2022
Influenza Research

New Way to Identify Influenza A Virus Lights Up When Specific Virus Targets are Present

June 20, 2022

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC